Hemispherx Ampligen Filing Will Jumpstart NDA Clock
This article was originally published in The Pink Sheet Daily
Biopharma accelerates evaluation of the Toll-like receptor-3 agonist as an adjuvant for HIV/AIDS and avian influenza vaccines.
You may also be interested in...
In some instances, the vaccine may have led to an increase in HIV infections.
Complete Ampligen NDA was submitted to FDA Oct. 10, CEO Carter tells “The Pink Sheet” DAILY.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.